The first product developed by Acrux was the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause.
Acrux has licenced its estradiol product to Gedeon Richter to commercialise in the European Union and other markets under the Lenzetto® brand. Lenzetto® was launched in 2016 and is now sold in over 30 countries across the European Union and other markets in South America.
Estradiol spray has been licensed to Padagis (formerly named Perrigo) for sale in the United States since 2009 where the product is marketed under the Evamist® brand.
About the Estradiol product
This estradiol product is different to other transdermal products. The spray applied is clear, generally dries in less than two minutes and has a low incidence of reported skin irritation.
Clinical studies have shown that estradiol delivered in the Acrux Estradiol formulation is absorbed through the skin and provides efficacious serum concentrations for the treatment of vasomotor symptoms in postmenopausal women. The fast-drying spray delivers a low dose of estradiol, resulting in therapeutic blood levels similar to the exposure range for other approved estrogen products.